Product Description
selective EZH2 inhibitor (Sourced from: https://pubmed.ncbi.nlm.nih.gov/31471312/)
Mechanisms of Action: EZH2 Inhibitor, EED Inhibitor
Novel Mechanism: Yes
Modality: Small Molecule
Route of Administration: Injection
FDA Designation: *
Approval Status: Not Approved
Approved Countries: None
Approved Indications: None
Known Adverse Events: None
Company: GSK
Company Location: Europe
Company Founding Year: 2000
Additional Commercial Interests: None
Clinical Description
Countries in Clinic:
Active Clinical Trial Count:
Recent & Upcoming Milestones
Highest Development Phases
Phase 1: Diffuse Large B-Cell Lymphoma|Lymphoma, Non-Hodgkin|Follicular Lymphoma|Multiple Myeloma
Trial ID |
Trial |
Phase |
Trial Status |
Disease |
Primary Completion Date |
Probability of Success |
Latest Trial Update Date |
Data Updated |
|---|---|---|---|---|---|---|---|---|
NCT02082977 |
NCT02082977 | P1 |
Terminated |
Lymphoma, Non-Hodgkin|Diffuse Large B-Cell Lymphoma|Multiple Myeloma|Follicular Lymphoma |
2017-06-20 |
2019-03-20 |
Treatments |